Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 48 studies | 83% ± 17% | |
pericyte | 30 studies | 50% ± 23% | |
smooth muscle cell | 29 studies | 40% ± 19% | |
connective tissue cell | 18 studies | 79% ± 20% | |
myofibroblast cell | 12 studies | 75% ± 26% | |
endothelial cell | 10 studies | 37% ± 17% | |
adipocyte | 8 studies | 34% ± 16% | |
mesothelial cell | 6 studies | 55% ± 14% | |
endothelial cell of lymphatic vessel | 5 studies | 50% ± 23% | |
adventitial cell | 5 studies | 90% ± 14% | |
macrophage | 4 studies | 30% ± 11% | |
chondrocyte | 4 studies | 53% ± 26% | |
hepatic stellate cell | 3 studies | 36% ± 2% | |
podocyte | 3 studies | 73% ± 22% | |
lymphocyte | 3 studies | 30% ± 6% | |
myeloid cell | 3 studies | 24% ± 6% | |
endothelial cell of vascular tree | 3 studies | 35% ± 18% | |
epithelial cell | 3 studies | 47% ± 21% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 7 studies | 33% ± 18% | |
heart | 7 studies | 26% ± 6% | |
intestine | 5 studies | 37% ± 14% | |
uterus | 5 studies | 43% ± 12% | |
adipose | 5 studies | 38% ± 22% | |
esophagus | 3 studies | 26% ± 5% | |
eye | 3 studies | 22% ± 6% | |
skin | 3 studies | 45% ± 20% | |
stomach | 3 studies | 33% ± 22% | |
breast | 3 studies | 25% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 161269.46 | 457 / 459 | 94% | 178.10 | 1047 / 1118 |
lung | 99% | 103100.78 | 574 / 578 | 92% | 112.14 | 1062 / 1155 |
ovary | 100% | 180347.12 | 180 / 180 | 73% | 71.47 | 313 / 430 |
bladder | 100% | 104081.57 | 21 / 21 | 67% | 58.23 | 336 / 504 |
esophagus | 85% | 78257.62 | 1234 / 1445 | 73% | 54.95 | 133 / 183 |
intestine | 85% | 52173.50 | 819 / 966 | 69% | 61.16 | 362 / 527 |
uterus | 99% | 118442.98 | 169 / 170 | 53% | 55.74 | 244 / 459 |
prostate | 71% | 31076.85 | 174 / 245 | 80% | 51.58 | 400 / 502 |
skin | 95% | 101259.48 | 1724 / 1809 | 44% | 31.99 | 210 / 472 |
thymus | 94% | 62564.27 | 616 / 653 | 43% | 29.94 | 259 / 605 |
stomach | 55% | 38318.55 | 196 / 359 | 78% | 70.48 | 222 / 286 |
adrenal gland | 91% | 47028.33 | 236 / 258 | 26% | 23.38 | 60 / 230 |
adipose | 99% | 151762.92 | 1196 / 1204 | 0% | 0 | 0 / 0 |
pancreas | 7% | 1920.26 | 24 / 328 | 92% | 185.77 | 163 / 178 |
heart | 95% | 97195.47 | 819 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 92% | 79167.25 | 1231 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 71% | 41.06 | 32 / 45 |
kidney | 46% | 18485.28 | 41 / 89 | 24% | 16.38 | 219 / 901 |
muscle | 46% | 14530.59 | 370 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 45% | 20.28 | 13 / 29 |
liver | 12% | 3186.36 | 27 / 226 | 29% | 15.91 | 118 / 406 |
brain | 0% | 104.29 | 11 / 2642 | 35% | 23.20 | 249 / 705 |
peripheral blood | 0% | 66.34 | 3 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0051901 | Biological process | positive regulation of mitochondrial depolarization |
GO_0090141 | Biological process | positive regulation of mitochondrial fission |
GO_0009887 | Biological process | animal organ morphogenesis |
GO_0016525 | Biological process | negative regulation of angiogenesis |
GO_0016239 | Biological process | positive regulation of macroautophagy |
GO_0010508 | Biological process | positive regulation of autophagy |
GO_1900747 | Biological process | negative regulation of vascular endothelial growth factor signaling pathway |
GO_0051897 | Biological process | positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0010596 | Biological process | negative regulation of endothelial cell migration |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0005796 | Cellular component | Golgi lumen |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0043202 | Cellular component | lysosomal lumen |
GO_0030021 | Molecular function | extracellular matrix structural constituent conferring compression resistance |
GO_0005539 | Molecular function | glycosaminoglycan binding |
GO_0003723 | Molecular function | RNA binding |
GO_0050840 | Molecular function | extracellular matrix binding |
GO_0005515 | Molecular function | protein binding |
Gene name | DCN |
Protein name | Decorin Decorin isoform 4 Decorin (Bone proteoglycan II) (PG-S2) (PG40) Decorin isoform 3 Decorin (Bone proteoglycan II) |
Synonyms | DKFZp686J19238 SLRR1B hCG_24110 |
Description | FUNCTION: May affect the rate of fibrils formation. FUNCTION: May affect the rate of fibrils formation. . FUNCTION: May affect the rate of fibrils formation. . FUNCTION: May affect the rate of fibrils formation. . FUNCTION: May affect the rate of fibrils formation. . FUNCTION: May affect the rate of fibrils formation. . FUNCTION: May affect the rate of fibrils formation. . FUNCTION: May affect the rate of fibrils formation. . |
Accessions | ENST00000552145.5 F8VUF6 Q6FH10 ENST00000551354.1 ENST00000552962.5 [P07585-1] F8VNW0 ENST00000425043.5 [P07585-3] ENST00000550563.5 ENST00000456569.2 [P07585-5] ENST00000546370.5 F8VX58 A0A0S2Z3L3 ENST00000546745.5 F8VWU0 ENST00000547568.6 [P07585-3] ENST00000441303.6 [P07585-4] H0YIH3 ENST00000550758.1 ENST00000546391.5 ENST00000549513.5 ENST00000550099.5 ENST00000393155.6 A0A0S2Z3L8 F8VU58 H0YI87 A0A7I2PRI8 ENST00000548218.1 F8VNV6 ENST00000547937.5 F8VSI3 P07585 ENST00000052754.10 [P07585-1] A0A0S2Z3J8 F8VXZ8 ENST00000420120.6 [P07585-2] |